World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
82
Citations
30512
World Ranking
3639
National Ranking
1815

Medicine

D-Index
85
Citations
33719
World Ranking
14438
National Ranking
7303

Overview

Mark M. Awad is affiliated with Harvard University in the United States and has contributed extensively to the field of medicine, with a particular focus on oncology and pulmonary and respiratory medicine. Their research spans multiple interconnected subfields including molecular biology, cancer research, and surgery.

The scientist's main topics of research cover several key areas:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Peptidase Inhibition and Analysis

Mark M. Awad has collaborated frequently with other researchers, including Biagio Ricciuti, Joao V. Alessi, Lynette M. Sholl, Federica Pecci, and Giuseppe Lamberti.

Their published work frequently appears in well-known venues related to oncology and cancer research, such as:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Annals of Oncology
  • JCO Precision Oncology

Among recent publications, some notable papers include:

  • "Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study" (2020, Journal of Clinical Oncology)
  • "A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer" (2020, Cell)
  • "Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial" (2020, The Lancet Oncology)
  • "Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway" (2020, Cancer Cell)
  • "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration" (2020, Nature Medicine)

The research portfolio demonstrates a focus on lung cancer therapies and immunotherapies, often integrating clinical trials and molecular investigations. This work contributes to advancing therapies in extensive-stage small-cell lung cancer, non-small-cell lung cancer, and other cancer types such as melanoma and bladder cancer.

Best Publications

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Corey J Langer;Shirish M Gadgeel;Hossein Borghaei;Vassiliki A Papadimitrakopoulou

  • The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

    Luc Friboulet;Nanxin Li;Ryohei Katayama;Christian C. Lee

  • Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

    Matthew D. Hellmann;Margaret K. Callahan;Mark M. Awad;Emiliano Calvo

  • Patient-derived models of acquired resistance can identify effective drug combinations for cancer

    Adam S. Crystal;Alice T. Shaw;Lecia V. Sequist;Luc Friboulet

  • A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

    Patrick A. Ott;Siwen Hu-Lieskovan;Bartosz Chmielowski;Ramaswamy Govindan

  • MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

    Mark Magdi Awad;Geoffrey Raymond Oxnard;David M Jackman;Daniel O. Savukoski

  • STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment

    Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Amir R. Aref

  • ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

    Justin F. Gainor;Anna M. Varghese;Sai-Hong Ignatius Ou;Sheheryar Kabraji

  • Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)

    Paul W. Sperduto;T. Jonathan Yang;Kathryn Beal;Hubert Pan

  • Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

    Charles M Rudin;Mark M Awad;Alejandro Navarro;Maya Gottfried

  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

    Neal Ready;Matthew D. Hellmann;Mark M. Awad;Gregory A. Otterson

  • Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.

    Catherine A Shu;Justin F Gainor;Mark M Awad;Codruta Chiuzan

  • Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors

    Diana Miao;Diana Miao;Claire A. Margolis;Claire A. Margolis;Natalie I. Vokes;Natalie I. Vokes;David Liu;David Liu

  • PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

    Mizuki Nishino;Nikhil H. Ramaiya;Mark M. Awad;Lynette M. Sholl

  • Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

    Mark M. Awad;Ryohei Katayama;Michele McTigue;Wei Liu

  • False positive plasma genotyping due to clonal hematopoiesis

    Yuebi Hu;Bryan C. Ulrich;Julianna Supplee;Yanan Kuang

  • Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

    Guillermo De Velasco;Youjin Je;Dominick Bossé;Mark M. Awad

  • Acquired Resistance to KRASG12C Inhibition in Cancer

    Mark M Awad;Shengwu Liu;Igor I Rybkin;Kathryn C Arbour

  • Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

    Kari J. Kurppa;Yao Liu;Ciric To;Tinghu Zhang

Frequent Co-Authors

Lynette M. Sholl
Lynette M. Sholl Brigham and Women's Hospital
Mizuki Nishino
Mizuki Nishino Harvard University
Pasi A. Jänne
Pasi A. Jänne Harvard University
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center
Justin F. Gainor
Justin F. Gainor Harvard University
Alice T. Shaw
Alice T. Shaw Harvard University
F. Stephen Hodi
F. Stephen Hodi Harvard University
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Scott J. Rodig
Scott J. Rodig Harvard University
Andrew D. Cherniack
Andrew D. Cherniack Broad Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees is a flexible way to expand your career options in biology and biochemistry. Many students interested in health sciences look into allied fields that complement their core studies. For example, those who want to combine life sciences with movement and wellness often pursue an online bachelor's in kinesiology, which opens doors in sports medicine, physical therapy, and fitness coaching.

For professionals aiming to advance quickly, options like the 1 year pmhnp program can prepare registered nurses for specialized roles in mental health. Similarly, the fastest post master's fnp certificate helps nurse practitioners transition efficiently into family primary care roles, which remain in high demand across the US.

Another popular pathway is nutrition science. An online dietetics programs offer affordable and convenient options for those passionate about food science, wellness, and public health. Each of these pathways helps biology and biochemistry graduates tailor their qualifications to diverse healthcare and science careers with real impact.

Best Scientists Citing Mark M. Awad

Trending Scientists

Recently Published Articles